Live Chat
Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Yong-Ku Kim, editor.
    Summary: This book reviews all aspects of major depressive disorder (MDD), casting light on its neurobiological underpinnings and describing the most recent advances in management. The book is divided into four sections, the first of which discusses MDD from a network science perspective, highlighting the alterations in functional and structural connectivity and presenting insights achieved through resting state functional MRI and the development of neuroimaging-based biomarkers. The second section examines important diagnostic and neurobiological issues, while the third considers the currently available specific treatments for MDD, including biofeedback, neurofeedback, cognitive behavioral therapy, acceptance and commitment therapy, neuromodulation therapy, psychodynamic therapy, and complementary and alternative medicine. A concluding section is devoted to promising emerging treatments, from novel psychopharmacological therapies through to virtual reality treatment, immunotherapy, biomarker-guided tailored therapy, and more. Written by leading experts from across the world, the book will be an excellent source of information for both researchers and practitioners.

    Contents:
    Section I. Re-thinking depression from a network perspective
    Chapter 1. Phenotype network and brain structural covariance network of major depression
    Chapter 2. Task MRI-based functional brain network of major depression
    Chapter 3. White matter-based structural brain network of major depression
    Chapter 4. The application of a machine learning-based brain MRI approach in major depression
    Chapter 5. Resting state functional MRI in major depression
    Chapter 6. Development of neuroimaging-based biomarkers in depressive disorder
    Section II. Current diagnostic and neurobiological issues
    Chapter 7. Challenges and strategies for current classifications of depressive disorders: proposal for future diagnostic standards
    Chapter 8. Epigenetics: a missing link between early life stress and depression
    Chapter 9. Glia- neuron communications and gut-brain axis in depression
    Chapter 10. Apoptosis and proliferation markers in major depression
    Chapter 11. A load to find clinically useful biomarkers for depression
    Chapter 12. Pharmacogenomic tests for diagnosis and treatment prediction in depression
    Section III. Current specific treatments for depression
    Chapter 13. Biofeedback and neurofeedback for depression: a critical review
    Chapter 14. Cognitive behavioral therapy and mindfulness based cognitive therapy for depressive disorders
    Chapter 15. Acceptance Commitment Therapy (ACT) for major depressive disorder
    Chapter 16. Neurostimulation therapies in depressive disorders
    Chapter 17. Ketamine in major depression : New rapid antidepressant
    Chapter 18. Psychodynamic therapy in depressive disorders
    Chapter 19. Well-being therapy in depressive disorders
    Chapter 20. Complementary and alternative medicine in the treatments of depressive disorders
    Chapter 21. Current psychopharmacology algorithm for major depressive disorder
    Section IV. Promising future treatments for depression
    Chapter 22. Novel psychopharmacology for depressive disorders
    Chapter 23. Cannabinoid agents for depressive disorders
    Chapter 24. Virtual Reality for the treatment of depressive disorders
    Chapter 25. Epigenetic Therapy in depressive disorders
    Chapter 26. Induced pluripotent stem (iPS) cells technology: potential therapeutic targets for depression
    Chapter 27. Vaccination and immunotherapy for major depression
    Chapter 28. Psychedelic Medicines in major depression: progress and future challenges
    Chapter 29. Precision Psychiatry: Biomarker guided Tailored Therapy for Effective Treatment and Prevention in major depression. .
    Digital Access Springer 2021
  • Article
    Casirola G, Invernizzi R, Ippoliti G, Marini G.
    Minerva Med. 1978 Jul 07;69(33):2217-34.
    The clinical and pathological features of amyloidosis are examined in the light of a classification based on anatomical models of amyloid distribution: 1) generalised amyloidosis, including primary and secondary sporadic forms, hereditary and familial amyloidosis, and senile amyloidosis; 2) local amyloidosis, including amyloid tumours, neoplasia with amyloid stroma, and other forms. The nature of amyloid is described. Morphological, ultrastructural, biochemical and immunochemical research has shown that: 1) amyloid is a fibrillar protein with a typical EM and X-ray diffraction appearance; 2) two main types of amyloid proteins exist, one related to Ig light chains and found in primary forms and in association with myeloma, the other (called AA proteins) being the main component of secondary forms and certain types of familial amyloidosis; 3) serum proteins structurally related to the AA proteins may be used as amyloid precursors. The cause and mechanisms of amyloid production are becoming clearer. In particular, a relation with the production of Igs has been established. Improved methods for the diagnosis and treatment of the disease will throw more light and the nature of amyloid and its protein precursors.
    Digital Access Access Options